A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia
In this interim analysis, gilteritinib 120 mg/day in combination with chemotherapy was well tolerated, with similar CRc rates to previous studies.
Authors
- Alexandra N. Heinloth
- Nahla Hasabou
- Masanori Kosako (ORCID: https://orcid.org/0000-0002-4981-9450)
- June‐Won Cheong (ORCID: https://orcid.org/0000-0002-1744-0921)
- Takayuki Ikezoe (ORCID: https://orcid.org/0000-0002-7858-278X)
- Masato Ikegaya
- Jason E. Hill (ORCID: https://orcid.org/0000-0003-2512-1661)
- Toshihiro Miyamoto (ORCID: https://orcid.org/0000-0002-6533-1594)
- Stanley C. Gill (ORCID: https://orcid.org/0009-0001-0063-8755)
- Takeshi Kadokura
- Wataru Terada
- Satoshi Morita (ORCID: https://orcid.org/0000-0001-5372-7113)
- Shuichi Miyawaki (ORCID: https://orcid.org/0000-0002-1173-4216)
- Koichi Akashi (ORCID: https://orcid.org/0000-0001-7763-5723)
- Hee‐Je Kim
- Yasushi Hiramatsu
- Masashi Sawa
- Tomoki Naoe
Institutions
- Kanazawa University (JP)
- Otsuka (Japan) (JP)
- Astellas Pharma (Japan) (JP)
- Kyoto University (JP)
- Severance Hospital (KR)
- Tokyo Metropolitan Ohtsuka Hospital (JP)
- Kyushu University Hospital (JP)
- MSD K.K. (Japan) (JP)
- Himeji Red Cross Hospital (JP)
- National Hospital Organization (JP)
- Fukushima Medical University Hospital (JP)
- Nagoya Medical Center (JP)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Yonsei University Health System (KR)
- Astellas Pharma (United States) (US)
- Catholic University of Korea (KR)
Publication Details
- Journal
- International Journal of Hematology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.1007/s12185-024-03840-x
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- Astellas Pharma US
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders